Is CNTB or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -122.29% -97.07% Oncobiologics N/A N/A -291.28%

Does the media prefer CNTB or OTLK?

In the previous week, Oncobiologics had 7 more articles in the media than Connect Biopharma. MarketBeat recorded 9 mentions for Oncobiologics and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.35 beat Oncobiologics' score of 0.79 indicating that Connect Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncobiologics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CRDL or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% Oncobiologics N/A N/A -291.28%

Does the media prefer CRDL or OTLK?

In the previous week, Oncobiologics had 8 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 9 mentions for Oncobiologics and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.93 beat Oncobiologics' score of 0.79 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncobiologics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EQ or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -61.43% -53.72% Oncobiologics N/A N/A -291.28%

Does the media refer more to EQ or OTLK?

In the previous week, Equillium had 8 more articles in the media than Oncobiologics. MarketBeat recorded 17 mentions for Equillium and 9 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.79 beat Equillium's score of 0.35 indicating that Oncobiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 4 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncobiologics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OTLK or SPRB more profitable?

Oncobiologics' return on equity of 0.00% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -291.28% Spruce Biosciences N/A -155.40% -101.67%

Do analysts prefer INDP or OTLK?

Oncobiologics has a consensus price target of $4.50, indicating a potential upside of 463.91%. Given Oncobiologics' stronger consensus rating and higher probable upside, analysts clearly believe Oncobiologics is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Oncobiologics 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is INDP or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Indaptus Therapeutics N/A -1,030.07% -299.69% Oncobiologics N/A N/A -291.28%

Does the media refer more to INDP or OTLK?

In the previous week, Oncobiologics had 7 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 9 mentions for Oncobiologics and 2 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 0.93 beat Oncobiologics' score of 0.79 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncobiologics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oncobiologics (OTLK) Competitors

$0.80 -0.01 (-1.46%)

Closing price 03:59 PM Eastern

Extended Trading

$0.84 +0.04 (+4.64%)

As of 04:13 PM Eastern

Compare

OTLK vs. CNTB, CRDL, EQ, SPRB, and INDP

Should you buy Oncobiologics stock or one of its competitors? MarketBeat compares Oncobiologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncobiologics include Connect Biopharma (CNTB), Cardiol Therapeutics (CRDL), Equillium (EQ), Spruce Biosciences (SPRB), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical products" industry.

How does Oncobiologics compare to Connect Biopharma?

Connect Biopharma (NASDAQ:CNTB) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by insiders. Comparatively, 2.8% of Oncobiologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Connect Biopharma currently has a consensus price target of $7.20, indicating a potential upside of 209.81%. Oncobiologics has a consensus price target of $4.50, indicating a potential upside of 463.91%. Given Oncobiologics' higher possible upside, analysts clearly believe Oncobiologics is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Oncobiologics had 7 more articles in the media than Connect Biopharma. MarketBeat recorded 9 mentions for Oncobiologics and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.35 beat Oncobiologics' score of 0.79 indicating that Connect Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncobiologics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Connect Biopharma has a beta of -0.22, suggesting that its share price is 122% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Oncobiologics' return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
Oncobiologics	N/A	N/A	-291.28%

Connect Biopharma has higher earnings, but lower revenue than Oncobiologics. Connect Biopharma is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,438.65	-$55.48M	-$1.15	N/A
Oncobiologics	$1.35M	82.79	-$62.42M	-$1.17	N/A

Summary

Connect Biopharma beats Oncobiologics on 10 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Cardiol Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 635.93%. Oncobiologics has a consensus price target of $4.50, indicating a potential upside of 463.91%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cardiol Therapeutics is more favorable than Oncobiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cardiol Therapeutics has higher earnings, but lower revenue than Oncobiologics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Oncobiologics	$1.35M	82.79	-$62.42M	-$1.17	N/A

In the previous week, Oncobiologics had 8 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 9 mentions for Oncobiologics and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.93 beat Oncobiologics' score of 0.79 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncobiologics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiol Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Oncobiologics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Oncobiologics	N/A	N/A	-291.28%

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Cardiol Therapeutics beats Oncobiologics on 9 of the 14 factors compared between the two stocks.

How does Oncobiologics compare to Equillium?

Equillium (NASDAQ:EQ) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Equillium has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

In the previous week, Equillium had 8 more articles in the media than Oncobiologics. MarketBeat recorded 17 mentions for Equillium and 9 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.79 beat Equillium's score of 0.35 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	4 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncobiologics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Equillium presently has a consensus target price of $7.57, indicating a potential upside of 139.75%. Oncobiologics has a consensus target price of $4.50, indicating a potential upside of 463.91%. Given Oncobiologics' higher probable upside, analysts clearly believe Oncobiologics is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

27.1% of Equillium shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 17.8% of Equillium shares are held by insiders. Comparatively, 2.8% of Oncobiologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Equillium has higher revenue and earnings than Oncobiologics. Equillium is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	4.86	-$22.40M	-$0.32	N/A
Oncobiologics	$1.35M	82.79	-$62.42M	-$1.17	N/A

Oncobiologics' return on equity of 0.00% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
Oncobiologics	N/A	N/A	-291.28%

Summary

Equillium beats Oncobiologics on 11 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Spruce Biosciences?

Oncobiologics (NASDAQ:OTLK) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 2.8% of Oncobiologics shares are held by insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Spruce Biosciences had 1 more articles in the media than Oncobiologics. MarketBeat recorded 10 mentions for Spruce Biosciences and 9 mentions for Oncobiologics. Spruce Biosciences' average media sentiment score of 0.88 beat Oncobiologics' score of 0.79 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncobiologics	Positive
Spruce Biosciences	Positive

Oncobiologics currently has a consensus price target of $4.50, indicating a potential upside of 463.91%. Spruce Biosciences has a consensus price target of $176.60, indicating a potential upside of 230.34%. Given Oncobiologics' higher probable upside, equities analysts plainly believe Oncobiologics is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Spruce Biosciences has higher revenue and earnings than Oncobiologics. Spruce Biosciences is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	82.79	-$62.42M	-$1.17	N/A
Spruce Biosciences	$4.91M	29.94	-$38.97M	-$36.60	N/A

Oncobiologics' return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Spruce Biosciences	N/A	-155.40%	-101.67%

Oncobiologics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.11, suggesting that its share price is 211% more volatile than the broader market.

Summary

Spruce Biosciences beats Oncobiologics on 10 of the 15 factors compared between the two stocks.

How does Oncobiologics compare to Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

In the previous week, Oncobiologics had 7 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 9 mentions for Oncobiologics and 2 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 0.93 beat Oncobiologics' score of 0.79 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indaptus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncobiologics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncobiologics' return on equity of 0.00% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
Oncobiologics	N/A	N/A	-291.28%

Oncobiologics has a consensus price target of $4.50, indicating a potential upside of 463.91%. Given Oncobiologics' stronger consensus rating and higher probable upside, analysts clearly believe Oncobiologics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 23.6% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 2.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Indaptus Therapeutics has higher earnings, but lower revenue than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Oncobiologics	$1.35M	82.79	-$62.42M	-$1.17	N/A

Indaptus Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

Summary

Oncobiologics beats Indaptus Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OTLK vs. The Competition

Export

Metric	Oncobiologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$111.76M	$3.35B	$6.44B	$12.47B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-0.68	18.72	23.87	24.40
Price / Sales	82.79	320.32	521.86	117.01
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	-1.33	6.80	9.99	6.73
Net Income	-$62.42M	$24.09M	$3.56B	$337.03M
7 Day Performance	7.84%	-2.48%	-0.87%	0.11%
1 Month Performance	N/A	N/A	N/A	-1.70%
1 Year Performance	-58.22%	48.95%	28.77%	34.24%

Oncobiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OTLK Oncobiologics	3.6434 of 5 stars	$0.80 -1.5%	$4.50 +463.9%	-56.2%	$111.76M	$1.35M	N/A	20	News Coverage Insider Trade Options Volume Gap Down
CNTB Connect Biopharma	3.8384 of 5 stars	$2.35 flat	$7.50 +219.1%	+175.0%	$147.97M	$60K	N/A	110	Insider Trade
CRDL Cardiol Therapeutics	2.3585 of 5 stars	$1.32 flat	$8.50 +543.9%	-14.5%	$147.60M	N/A	N/A	20	Positive News
EQ Equillium	2.293 of 5 stars	$2.26 flat	$7.67 +239.2%	+771.1%	$142.89M	$41.10M	N/A	40
SPRB Spruce Biosciences	2.7008 of 5 stars	$51.08 flat	$186.60 +265.3%	+906.2%	$140.57M	$4.91M	N/A	20	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OTLK) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncobiologics (OTLK) Competitors

OTLK vs. CNTB, CRDL, EQ, SPRB, and INDP

How does Oncobiologics compare to Connect Biopharma?

Summary

How does Oncobiologics compare to Cardiol Therapeutics?

Summary

How does Oncobiologics compare to Equillium?

Summary

How does Oncobiologics compare to Spruce Biosciences?

Summary

How does Oncobiologics compare to Indaptus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncobiologics (OTLK) Competitors

OTLK vs. CNTB, CRDL, EQ, SPRB, and INDP

How does Oncobiologics compare to Connect Biopharma?

Do institutionals & insiders believe in CNTB or OTLK?

Do analysts recommend CNTB or OTLK?

Does the media prefer CNTB or OTLK?

Which has more risk and volatility, CNTB or OTLK?

Is CNTB or OTLK more profitable?

Which has higher earnings & valuation, CNTB or OTLK?

Summary

How does Oncobiologics compare to Cardiol Therapeutics?

Do analysts prefer CRDL or OTLK?

Which has higher valuation & earnings, CRDL or OTLK?

Does the media prefer CRDL or OTLK?

Which has more risk and volatility, CRDL or OTLK?

Is CRDL or OTLK more profitable?

Do institutionals & insiders hold more shares of CRDL or OTLK?

Summary

How does Oncobiologics compare to Equillium?

Which has more volatility & risk, EQ or OTLK?

Does the media refer more to EQ or OTLK?

Do analysts rate EQ or OTLK?

Do institutionals & insiders believe in EQ or OTLK?

Which has preferable earnings and valuation, EQ or OTLK?

Is EQ or OTLK more profitable?

Summary

How does Oncobiologics compare to Spruce Biosciences?

Do institutionals and insiders hold more shares of OTLK or SPRB?

Does the media prefer OTLK or SPRB?

Do analysts recommend OTLK or SPRB?

Which has better earnings & valuation, OTLK or SPRB?

Is OTLK or SPRB more profitable?

Which has more volatility & risk, OTLK or SPRB?

Summary

How does Oncobiologics compare to Indaptus Therapeutics?

Does the media refer more to INDP or OTLK?

Is INDP or OTLK more profitable?

Do analysts prefer INDP or OTLK?

Do insiders & institutionals believe in INDP or OTLK?

Which has better valuation and earnings, INDP or OTLK?

Which has more risk & volatility, INDP or OTLK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools